In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: potential for clinical application.

doi:10.1002/(SICI)1098-1004(1998)11:4<259::AID-HUMU1>3.0.CO;2-W

Back to search

Article

In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: potential for clinical application.

Human mutation - 1 Jan 1998

Blakley R L, Sorrentino B P

Abstract excerpt

Mammalian cells cultured in the presence of the chemotherapeutic agent, methotrexate, develop resistance to this drug. Sometimes this is due to mutations in the gene for dihydrofolate reductase, the primary target of methotrexate. However, it has not been possible to link such polymorphism to res...

Topics

Bone Marrow Transplantation
Cell Line
Drug Resistance
Escherichia coli
Genetic Therapy
Genetic Variation
Hematopoiesis
Humans
Methotrexate
Mutagenesis, Site-Directed
Mutation
Tetrahydrofolate Dehydrogenase

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.